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Aims: Characterization of neointimal tissue is essential to understand the pathophysiology of in-stent restenosis
(ISR) after drug eluting stent (DES) implantation. Using optical coherence tomography (OCT), we compared the
morphologic characteristics of ISR between ﬁrst and second generation DES.
Methods and Results: OCT was performed in 66 DES-ISR, deﬁned as N50% angiographic diameter stenosis within
the stented segment. Patients with ISR of ﬁrst generation sirolimus-eluting stents (SES), paclitaxel eluting stents
(PES) and second generation zotarolimus-eluting stents (ZES), everolimus-eluting stents (EES) and biolimus-
eluting stents (BES) were enrolled. Quantitative and qualitative ISR tissue analysis was performed at 1-mm
intervals along the entire stent, and categorised as homogeneous, heterogeneous and neo-atherosclerosis. The
presence of microvessels and peri-strut low intensity area (PSLIA) was determined in all ISR. Neoatherosclerosis
was identiﬁed by lipid, calcium and thin-cap ﬁbro-atheroma (TCFA) like lesions. We compared the two DES
generations at both early (b1 year) and late (N1 year) follow-ups.
In second generation DES a heterogeneous pattern was prevalent both before and after 1 year (57.1% and 58.6%
respectively). Neo-atherosclerosis was more common in the early period in ﬁrst generation DES (19.4% vs 11.7%,
p b 0.01), but after one year was more prevalent in second generation DES (7.0% vs 19.3%, p b 0.01). Similar
prevalence of TCFAs was observed in both groups in all comparisons.
Conclusions: When ISR restenosis occurs in second generation DES, the current data suggest a different time
course and different morphological characteristics from ﬁrst generation. Future prospective studies should
evaluate the relationship between ISR morphology, time course and clinical events.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Although a signiﬁcant reduction in the rate of in-stent restenosis
(ISR) has been observed with ﬁrst and second generation (G1 and G2)
drug eluting stents (DES) compared with bare metal stents (BMS),
this event still limits long term outcomes after percutaneous coronary
intervention (PCI) (1,2). However, the basis for this observation is not
yet fully understood. Optical coherence tomography (OCT) is theydney Street, London SW3 6NP,
z).
ript.
nd Ltd. This is an open access article upreferred modality to study arterial healing after stent implantation.
Due to its high resolution, OCT can disclose plaque morphology with a
sensitivity close to histology and provide an accurate assessment of
stent deployment, with special focus on the number and distribution
of covered struts (3,4). Recently, OCThas been used for the characteriza-
tion of ISR and different tissue patterns have been described (5,6).
Studies of DES-ISR are limited but there is an evidence that neointimal
hyperplasia after DES may be more heterogeneous and occur earlier
than the ﬁbrotic intimal hyperplasia observed after BMS implantation
(7,8). Furthermore, there is a histological evidence of neoatherosclerotic
tissue growth, mainly described within ﬁrst generation DES-ISR, which
is characterized by lipid and/or calciumdeposition,macrophage inﬁltra-
tion and necrotic core formation. In some cases these lesions are almost
indistinguishable from thin-cap-ﬁbro-atheroma (TCFA) lesions found in
native plaques (8,9) which are consistently shown to correlate withnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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compatibility, have drastically reduced restenosis and stent thrombosis
when compared with G1 DES (13–16). However, ISR has also been
described with these new generation devices.
The aim of this study was to compare the morphologic characteris-
tics of neo-intimal tissue in a consecutive series of ISR of G1 and G2
DES studied with OCT.
2. Methods
2.1. Study design and population
All consecutive patients with one or more ISR in a G1 or G2 DES,
studiedwith OCTbetween January 2007 andDecember 2012, were con-
sidered for the study. ISR was deﬁned as angiographically documented
diameter stenosis greater than 50% within the stented segment. The
region of interest extended from the distal to the proximal stent edge,
excluding the margins. As in previous pathologic ISR studies (8), we
considered overlapping and consecutive stents as one lesion, while
stents separated by more than 5 mm were considered as separate le-
sions. Patients included in our study underwent coronary angiography
as clinically indicated, due to stable angina or NSTE-acute coronary
syndromes, or as elective scheduled angiographic follow-up (because
of the type of lesion previously treated [left main or equivalent] or as
part of approved DES trials) (17,18). The use of intravascular imaging
with IVUS or OCT is routinely practised in our centre to diversify the
treatment of ISR based on its prevalent mechanism (underexpansion
vs hyperproliferation) as indicated and explained in the informed con-
sent approved by the institutional review board. We excluded patients
with total occlusion, ST-segment elevation myocardial infarction,
cardiogenic shock, serum creatinine N2 mg/dl and bare metal stent ISR.
2.2. Quantitative coronary angiography
Quantitative coronary angiography (QCA) was performed ofﬂine by a
skilled analyzer blinded to patients' clinical characteristics and OCT anal-
ysis, using dedicated cardiovascular measurement software (QAngio XA
7.1 Medis Medical Imaging System, Leiden, The Netherlands) on a single,
selected 2D end-diastolic image frame. Care was taken to select projec-
tions and frameswithminimal foreshortening and vessel overlap, analyz-
ing the view that revealed the highest degree of stenosis. After careful
calibration, lesion length, proximal anddistal references,minimal luminal
diameter (MLD) and percent diameter stenosis (%DS) were calculated.
Based on QCA results, lesions were classiﬁed as focal restenosis:
b10 mm in length, or diffuse restenosis: N10 mm in length (19).
2.3. Optical coherence tomography imaging and analysis
The OCT images were acquired, using a non-occlusive technique,
through a 2.7 Fr C7 Dragonﬂy Imaging Catheter (LightLab Imaging Inc.,
Westford,MA, USA), ﬂushedwith undiluted contrast dye and calibrated
before the acquisition,whichwas inserted distal to the lesion of interest.
A mechanical pullback at a speed of 20 mm/s was started during
continuous automatic ﬂushing of 2–5 ml/s of iodixanol (Visipaque™
320 mg I/ml GE Healthcare, Amersham, UK) to ensure blood clearance
from the coronary arteries, using a Medrad injector (Medrad Inc.,
Warrendale, PA, USA).
Quantitative and qualitative OCT analyses were performed off-line
by agreement of two experienced analysts, blinded to clinical and angio-
graphic lesion characteristics using commercial software (LightLab; St.
Jude, Minneapolis, MN, USA), at every 1mm cross section (CS) through-
out the pullback from the distal to the proximal stent edge. Quantitative
measurements included lumen and stent cross-sectional areas (CSA)
(automatically traced and manually adjusted when required), neointi-
mal hyperplasia (NIH) area (stent area–lumen area), percentage of
NIH area (NIH area / stent area × 100) (Fig. 1) (20). For this analysis,only CSs with a percentage of NIH area ≥50% have been considered as
effective part of the restenotic segment within stent (20).
Owing to a lack of consensus regarding the classiﬁcation of ISR
optical patterns and their histopathological basis, we analysed every
evaluable cross section and adopted previously reported qualitative
criteria for this analysis (6,9) (Fig. 2): 1) homogeneous neointima;
2) heterogeneous neointima; and 3) neo-atherosclerosis. The homoge-
neous pattern consists of tissue with uniform optical properties and
no focal variation in backscattering. Heterogeneous tissue was iden-
tiﬁed by the presence of several variations in the optical backscatter-
ing properties and sub-classiﬁed in: layered pattern, consisting in
concentric layers with different optical properties (thick adluminal
high scattering layer and an abluminal low scattering layer), patchy
pattern, irregular and highly echo-lucent regions throughout the
layers, and speckled pattern, restenotic tissue with heterogeneous
speckled bands (6,21). We deﬁned neo-atherosclerosis as ISR show-
ing optical areas consistent with at least one of the following
features: lipids, diffusely bordered, signal-poor regions; calcium as
well-delineated, low back-scattering heterogeneous regions; and
thin-cap ﬁbro-atheroma (TCFA) plaques, with a ﬁbrous cap thickness
≤65 μm and an angle of lipid tissue ≥180 showing relevant signal
attenuation (3,22). In these neo-atherosclerotic lesions, we also
identiﬁed the presence of macrophages, multiple strong back reﬂec-
tions, resulting in a relatively high OCT signal variance within the
ﬁbrous cap (23). Hence, in the presence of the well deﬁned neo-
atherosclerotic features reported above, we classiﬁed the ISR as
neo-atherosclerosis, while we deﬁned the heterogeneous group as
those with an ISR optical pattern which was neither homogeneous
nor neoatherosclerotic tissue.
Furthermore, in all lesions we identiﬁed the presence of:microvessels,
low backscattering structure with a diameter b200 μm; peri-strut low
intensity area (PSLIA) deﬁned as a region around stent strutswith homog-
enous lower intensity than surrounding tissue,without signal attenuation
(24); malapposed struts, when the axial distance from DES strut to the
luminal surfacewas longer than the strut/polymer thickness (25), exclud-
ing bifurcations; and uncovered struts, NIH thickness equal to 0 μm (26).
The decision to perform a dilatation before proceeding to OCT acqui-
sition was left to the operator's discretion on the basis of the angio-
graphic ﬁndings. In the event of a tight ISR lesion, pre-dilation with a
2.0 semi-compliant balloon, inﬂated at nominal pressure was allowed.
Since balloon inﬂation may create a rupture of the ﬁbrous cap, we
excluded from our analysis disrupted intima like lesions and the
presence of intraluminal material.
2.4. Statistical analysis
Categorical variables are expressed as numbers (percentages) and
comparisons between groups were performed with χ2 or Fisher's
exact test. Continuous variables are expressed as the mean ± standard
deviation and compared with Independent T-test. The primary analysis
compared ISR characteristics at early follow-up (less than 1 year) and
late follow-up (more than 1 year) within the ﬁrst or the second gener-
ation groups. Next, the comparison was performed between genera-
tions, within the early or late period (20). A p value b0.05 was
considered statistically signiﬁcant. All statistical analyses were per-
formed using the SPSS software (SPSS Inc. Version 20, Chicago, Illinois).
2.5. Results
A total of 66 ISR lesions were identiﬁed in 41 consecutive patients
enrolled in this study. We found 44 ISR within G1 DES: 21 sirolimus-
eluting stents (SES) (Cypher SELECT, Cordis, Miami Lakes, FL, USA)
and 23 paclitaxel-eluting stents (PES) (Taxus EXPRESS and Liberté,
Boston Scientiﬁc, Natick, MA, USA). We also identiﬁed 22 ISR lesions
in G2 DES: of which 11 everolimus-eluting stents (EES) (9 Xience,
Abbott Vascular, Santa Clara, CA, USA; and 2 Promus, Boston Scientiﬁc,
Fig. 1. Quantitative optical coherence tomography analysis. Representation of measured areas. CSA: cross sectional area; NIH: neointimal hyperplasia.
Fig. 2. Qualitative optical coherence tomography analysis. For deﬁnitions, refer in the text. 1) Homogeneous pattern of ISR. 2) Heterogeneous patterns subsequently subdivided in three
subtypes: 2a) layered pattern; 2b) patchy pattern; and 2c) speckled pattern. 3) Neo-atherosclerosis and its main features: 3a) lipid plaque; 3b) calcium deposit; 3c) thin-cap ﬁbro-
atheroma; and 3d) detail of macrophage presence in a lipid plaque. 4) Miscellaneous ISR characteristics: 4a) microvessels; 4b) peri-strut low intensity areas; 4c) overlapping stents;
and 4d) malapposed struts.
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71K. Kilickesmez et al. / IJC Heart & Vessels 3 (2014) 68–74Natick, MA, USA) 10 zotarolimus-eluting stents (ZES) (Resolute,
Medtronic, Santa Rosa, CA, USA) and 1 biolimus-eluting stent (BES)
(BioMatrix Flex, Biosensors Inc, Newport Beach, CA, USA) (Fig. 3).
Coronary angiography was clinically driven in 58.2% of cases and
electively scheduled in the remaining. Only 5 lesions (7.6%) required
balloon pre-dilatation before OCT pullback.
2.6. Clinical characteristic
Baseline patients' clinical characteristics are shown in Table 1. There
were no major differences between groups with the exception of a
higher prevalence of previous myocardial infarction within G2 group
in those with longer follow-up compared with patients with shorter
follow-up (p = 0.04). More often the left circumﬂex was the culprit
artery in the early follow-up of G1 compared with G2 DES (p = 0.04).
The rate of use of ACE-inhibitors differed among groups.
2.7. QCA analysis
QCA analyses are summarised in Table 2. Within G1 DES focal
restenosis predominated, whereas in G2 ISR a diffused pattern was
prevalent before 1 yearwith focal ISRmore frequent at later time points
(p = 0.02).
Quantitative analyses did not differ between early and late ISR of G1
DES. In the G2 group, the earlier lesions were signiﬁcantly longer and
with lower mean MLD and MLA, as well as higher %DS (p b 0.01).
The stent types within each DES generation were similar. Time from
stent implantation to the index coronary angiographywas not different
within the early phase between groups of DES,while in the late compar-
ison itwas signiﬁcantly longer for G1 thanG2DES (37.0 vs 15.8 months,
respectively, p b 0.01).
2.8. OCT analysis
The quantitative analysis showed similar lesion length among
groups. We found different mean absolute values of stent CSA and NIH
CSA between generations and that the percentage of NIH CSA was
lower for G2 DES both in the early and the late period (p b 0.01)
(Table 3).
The qualitative analysis performed in the entire stent is reported in
Table 4 and Fig. 4. A homogeneous pattern predominated in both early
and late G1 DES-ISR, increasing overtime, while the heterogeneous
and neoatherosclerotic lesions were less prevalent in the early phase
and became even more infrequent at later time points (p b 0.01 in all
comparisons). In G2 DES, we found a heterogeneous pattern more
frequently at both early and late time points. The homogeneous pattern
tended to become less prevalent overtime, while the frequency of neo-
atherosclerotic lesions tended to increase (p b 0.01 in all comparisons).Fig. 3. Schematic view of enrolled stents, according to generation, eluted drug and brand.
For acronyms see “Results” chapter.TCFAs as well as macrophages were rare and their prevalence did
not differ between generations and overtime. Microvessels were more
common in the early period in G1 ISR, but then decreased in prevalence;
PSLIA was less common in G1 but more prevalent in G2 DES (p b 0.01).
We found similar prevalence of overlapping andmalapposed CSs in our
analysis, however a signiﬁcant increase in the number of uncovered
struts was found associated with G1 ISR overtime.
3. Discussion
ISR is still themain reason of PCI failure and its predictors seem to be
largely the same across the spectrum of BMS, G1 and G2 DES (27). De-
spite shared trigger factors, several data suggest a different composition
of the restenotic tissue within different devices (7–9). Our study, focus-
ing on the evaluation of vascular healing after stent deployment using
quantitative and qualitative OCT assessment, depicts a different pattern
of ISR between G1 and G2 DES. We compared the two generations at
two separate time points, before and after 1 year. Furthermore we
analysed the differences of ISR patternwithin each generation overtime.
3.1. Comparison between ﬁrst and second generation DES
We showed that ISR in G1 DES hadmainly a homogeneous OCT pat-
tern before and after one year, whereas in G2 DES the heterogeneous
features were prevalent. In both generations the percentage of CSs
with neo-atherosclerosis remained below 20% and the absolute
prevalence was similar between generations. Similar prevalence of
TCFAs appeared between generations.
ISR is thought to be a manifestation of abnormal vessel healing after
stenting and provides the anatomic substrate for target lesion revascu-
larization (TLR) and possibly acute coronary syndromes (7,28). Al-
though there are few data on the histopathological basis of OCT-ISR
patterns, the homogeneous type is thought to be themore common ex-
pression of the uncontrolled neointimal cell proliferation typical of BMS.
The heterogeneous pattern, sometimes resembling neoatherosclerotic
lesions, seems to be more frequent in later phases and in DES (22). Dif-
ferences in the type of restenosis observed in different DES types have
been previously reported (7–9). The underlying processes are likely
multifactorial though the precisemechanisms remain unknown. Exper-
imental evidence suggests that neo-atherosclerosis is associated with
delayed arterial healing compounded by lethal injury to smoothmuscle
and endothelial cells (29). Therefore, the heterogeneous OCT images in
DES may represent phenomena such as peri-strut inﬂammation. DES
structure itself can inﬂuence vessel healing. Variables like different
stent platforms, strut thickness, durability of the polymer, kinetics of
drug release as well as post-deployment optimisation can explain
differences observed in ISR observed in different DES platforms.
There is no consensus on the interpretation of different optical pat-
terns and its histopathological basis. Previous studies demonstrated
that restenotic tissue with speckled pattern exhibited myxomatous
neointima tissue, containing extracellular matrix with proteoglycans
(30,31). DES suppress the immunological response of the treated arteri-
al wall. Therefore, delayed arterial healing, including replacement of ex-
tracellular matrix by smooth muscle cells or collagen, might contribute
to this speckled image. The layered pattern may arise from a difference
in smooth muscle cell density and orientation along the radial axis of
ISR, with a more compact and concentric orientation in the inner lumi-
nal border, with reduced density and longitudinal orientation toward
the vessel exterior. Alternatively the ﬁndings may be explained by the
progressive attenuation of light travelling through the tissue (6).
Conversely, neo-atherosclerosis, as reported in the “methods”, is recog-
nized according to well deﬁned OCT features.
Many clinical studies have shown that G2 DES have superior efﬁcacy
and safety proﬁle than G1 DES (13–15,17). We need to emphasize that
the relationship between ISR morphology determined by OCT and clin-
ical outcome is not established. In this study, only angiographically
Table 1
Baseline clinical characteristics, analysis per patients.
Variable First generation (n = 30) p Second generation (n = 11) p p* p**
≤1 year (n = 9) N1 year (n = 21) ≤1 year (n = 7) N1 year (n = 4)
Males 8 (88.9) 18 (85.7) 0.81 6 (85.7) 4 (100.0) 0.43 0.85 0.42
Age, years 63.9 ± 7.1 69.7 ± 8.7 0.09 67.9 ± 17.3 61.7 ± 7.4 0.52 0.54 0.10
Diabetes 3 (33.3) 7 (33.3) NA 5 (71.4) 1 (25.0) 0.14 0.13 0.74
Hypertension 7 (77.8) 17 (81.0) 0.84 6 (85.7) 3 (75.0) 0.66 0.69 0.79
High cholesterol 9 (100.0) 18 (85.7) 0.23 7 (100.0) 4 (100.0) NA NA 0.42
History of CAD 6 (66.7) 11 (52.4) 0.69 4 (57.1) 3 (75.0) 0.55 0.70 0.40
Current smoker 3 (33.3) 8 (38.1) 0.80 4 (57.1) 2 (50.0) 0.82 0.34 0.66
Previous CABG 3 (33.3) 10 (47.6) 0.69 5 (71.4) 1 (50.0) 0.48 0.13 0.93
Previous MI 6 (75.0) 14 (73.7) 0.94 2 (33.3) 4 (100.0) 0.04 0.12 0.25
Indication to PCI
Stable angina 3 (33.3) 11 (52.4) 0.34 4 (57.1) 2 (50.0) 0.82 0.34 0.93
ACS 0 (0.0) 4 (19.0) 0.16 0 (0.0) 0 (0.0) NA NA 0.34
Planned follow-up 6 (66.7) 6 (28.6) 0.10 3 (42.9) 2 (50.0) 0.82 0.34 0.40
Vessel with ISR 0 (0.0) 1 (4.8) 0.51 0 (0.0) 0 (0.0) NA NA 0.65
LM 3 (33.3) 8 (38.1) 0.80 2 (28.6) 2 (50.0) 0.48 0.84 0.66
LAD 4 (44.4) 7 (33.3) 0.69 0 (0.0) 1 (25.0) 0.17 0.04 0.74
LCX 2 (22.2) 2 (9.5) 0.35 2 (28.6) 1 (25.0) 0.89 0.77 0.38
RCA 0 (0.0) 1 (4.8) 0.51 0 (0.0) 0 (0.0) NA NA 0.67
LIMA 0 (0.0) 2 (9.5) 0.34 3 (42.9) 0 (0.0) 0.13 0.03 0.52
Venous graft
Medications 8 (88.9) 17 (85.0) 0.78 5 (71.4) 2 (66.7) 0.88 0.38 0.44
Statin 1 (11.1) 12 (60.0) 0.01 5 (71.4) 0 (0.0) 0.04 0.01 0.05
ACE-I 9 (100.0) 20 (100.0) NA 7 (100.0) 3 (100.0) NA NA NA
ASA
Continuous variables are expressed as the mean ± SD; categorical variables as number (%). ACE-I: angiotensin convertor enzyme inhibitor; ACS: acute coronary syndrome; ASA: acetyl
salicylic acid; CABG: coronary artery bypass graft; CAD: coronary artery disease; ISR: in-stent restenosis; LAD: left anterior descending artery; LCX: left circumﬂex; LIMA: left internal
mammary artery; LM: leftmain artery; MI:myocardial infarction; OCT: optical coherence tomography; RCA: right coronary artery. p: comparisonwithin eachDES generation; p*:comparison
of early ISR between generations; p**: comparison of late ISR between generations.
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healing process of the stent types reported or from less pronounced in-
stent proliferation not enrolled in our registry. Moreover, we support
the hypothesis that the dichotomous distinction in homogeneous and
heterogeneous patterns does not have a clinical correlation by itself. No
data exist about the risk of clinical events correlated with a layered, as
well as patchy or speckled pattern. As regards neo-atherosclerosis,
relevant target in our analysis, a correlation with plaque instability and
clinical events is currently a hypothesis (10–12). For instance, Kang
et al. reported OCT ﬁndings indicating that stent neoatherosclerosis was
frequently identiﬁed in patients with DES ISR, including TCFAs. Because
the last feature was more likely to be found in patients presenting unsta-
ble angina, they supported the concept that these ﬁndingswere similar toTable 2
Angiographic and QCA data, analysis per lesion.
Variable First generation (n = 44) p
≤1 year (n = 13) N1 year (n = 31)
Restenosis pattern
Focal 11 (84.6) 20 (64.5) 0.
Diffuse 2 (15.4) 11 (35.5) 0.
QCA data
Lesion length, mm 7.7 ± 4.5 12.2 ± 8.8 0.
RD, mm 2.9 ± 0.6 3.0 ± 0.7 0.
MLD, mm 1.1 ± 0.6 1.0 ± 0.5 0.
MLA, mm2 1.2 ± 0.9 1.3 ± 1.9 0.
Diameter stenosis, % 64.0 ± 16.2 67.0 ± 15.7 0.
Stent type
Cypher 5 (38.5) 16 (51.6) 0.
Taxus 8 (61.5) 15 (48.4)
Xience – –
Promus – –
Resolute – –
BioMatrix – –
Time from previous stent to ISR 10.0 ± 2.8 37.0 ± 18.3 b0
Continuous variables are expressed as the mean ± SD; categorical variables as number (%
QCA: quantitative coronary analysis. RD: reference diameter; p: comparison within each D
late ISR between generations.vulnerable plaques in native coronary arteries and more prone to clinical
instability (32). Interestingly, in our study, TCFAs have been rarely
found and, although numerically lower in second generation DES, their
prevalence was similar comparing DES generations and in the overtime
analysis within generations. The prognostic role of neo-atherosclerosis
in ISR needs further investigations.
Neovascularization may play a role in plaque haemorrhage within
de-novo lesions and inﬂuence clinical outcome (33,34). In this analysis
of ISR, despite being rare, microvessels appeared signiﬁcantly more
common in early ISR of G1 DES. The role of neovascularization in ISR
natural history is unknown.
Although our population was selected in relation to the presence of
redundant intra-luminal tissue, typical of ISR, our results are consistedSecond generation (n = 22) p p* p**
≤1 year (n = 14) N1 year (n = 8)
28 5 (35.7) 7 (87.5) 0.02 0.02 0.40
28 9 (64.3) 1 (12.5) 0.02 0.03 0.40
09 18.7 ± 14.4 7.5 ± 3.6 0.01 0.02 0.15
48 3.0 ± 0.6 3.0 ± 0.8 0.89 0.65 0.98
75 0.8 ± 0.4 1.4 ± 0.5 b0.01 0.12 0.07
80 0.6 ± 0.5 1.6 ± 1.2 b0.01 0.06 0.65
63 71.7 ± 16.2 54.4 ± 7.1 b0.01 0.22 b0.01
52 – – 0.09 NA NA
– –
3 (21.4) 6 (75.0)
2 (14.3) 0 (0.0)
8 (57.1) 2 (25)
1 (7.1) 0 (0.0)
.01 8.1 ± 3.1 15.8 ± 4.0 b0.01 0.12 b0.01
). ISR: in-stent restenosis; MLA: minimal lumen area; MLD: minimal lumen diameter;
ES generation; p*: comparison of early ISR between generations; p**: comparison of
Table 3
Quantitative OCT analysis per cross-section with ISR N 50%.
Variable First generation (n = 143) p Second generation (n = 89) p p* p**
≤1 year (n = 43) N1 year (n = 100) ≤1 year (n = 70) N1 year (n = 19)
Mean stent CSA, mm2 5.0 ± 2.1 5.1 ± 1.7 0.88 8.4 ± 3.2 4.3 ± 1.1 b0.01 b0.01 0.01
Mean lumen CSA, mm2 1.6 ± 1.3 1.6 ± 1.2 0.86 3.2 ± 1.3 1.9 ± 0.5 b0.01 b0.01 0.08
NHI CSA, mm2 3.5 ± 1.0 3.5 ± 0.9 0.91 5.2 ± 2.4 2.4 ± 0.7 b0.01 b0.01 b0.01
NIH area, % 72.1 ± 12.1 71.4 ± 14.9 0.79 61.1 ± 8.4 55.5 ± 5.2 b0.01 b0.01 b0.01
Restenosis length, mm 7.1 ± 11.9 5.3 ± 6.7 0.62 6.4 ± 6.4 4.7 ± 2.5 0.50 0.86 0.88
Continuous variables are expressed as the mean ± SD. CSA: cross sectional area; NIH: neo-intimal hyperplasia. p: comparison within each DES generation; p*: comparison of early ISR
between generations; p**: comparison of late ISR between generations.
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DES after OCT follow-up (25,26). This ﬁnding supports the concept of
heterogeneity of vascular healing response after stenting, with possible
co-existence of hyperplasic tissue and uncovered struts in adjacent
segment (35,36), possibly due to uneven distribution of polymer and
loading drug eluted, and overlapping and different deployment results
in each CS.
The quantitative lesion analysis performed by both QCA and OCT
showed less severe features within G2 DES, conceptually in line with
the lower incidence of restenosis and TLR coming from clinical studies
(13–16).
3.2. Comparison overtime within generations
This study, missing serial OCT analysis of the target restenotic
lesions, does not claim to represent a reliable report of ISR pattern evo-
lution overtime. Hence the interpretation of ISR pattern changes, based
on an indirect comparison of OCT ﬁndings coming from lesions with a
different follow-up, is performed aware of this limitation and is only
hypothesis generating.
We found that in G1 DES the homogeneous pattern was prevalent
before 1 year and even more represented afterwards. On the contrary
the other patterns seemed to decrease. The heterogeneous pattern
had higher prevalence in G2 both before and after 1 year, with the
same absolute percentage, while neo-atherosclerosis was signiﬁcantly
more prevalent in the second period.
Several pathological studies conﬁrmed that neoatherosclerotic
features can be found in some restenotic lesions, often related to the
time post-stent implantation (32,37). Habara et al. observed neo-
atherosclerotic restenosis more frequently within DES than BMS (31%
vs 16%; p b 0.001). In the former group neo-atherosclerosis appeared to
manifest earlier (420 days vs. 2160 days respectively, p b 0.001) (9).
Available data suggest a trend toward more rapid neoatheroscleroticTable 4
OCT qualitative analysis in the entire stent.
Variable First generation (n = 1036) p
≤1 year (n = 309) N1 year (n = 727)
Homogeneous 132 (42.7) 515 (70.8) b0.01
Heterogeneous 117 (37.9) 161 (22.2) b0.01
Layered 9 (7.7) 69 (42.9)
Patchy 87 (75.0) 74 (46.0)
Speckled 21 (18.1) 18 (11.2)
Neo-atherosclerosis 60 (19.4) 51 (7.0) b0.01
Lipids 59 (19.1) 34 (4.7) b0.01
Calcium 20 (6.5) 10 (1.4) b0.01
TCFA 3 (1.0) 7 (1.0) 0.99
Macrophages 3 (1.0) 6 (0.8) 0.73
Microvessels 8 (2.6) 2 (0.3) b0.01
PSLIA 48 (15.5) 65 (8.9) b0.01
Overlapping CSs 31 (10.0) 65 (8.9) 0.56
Malapposed struts 0 (0.0) 12 (1.7) 0.08
Uncovered struts 3 (1.0) 22 (3.0) 0.04
Categorical variables are expressed as number (%). CSs: cross-sections; OCT: optical coherence
tion; p*: comparison of early ISR between generations; p**: comparison of late ISR between gechanges in SES, although the frequency of neo-atherosclerosis in both
PES and SESwas higher than that in BMS (8). The heterogeneous pattern,
aswell as neo-atherosclerosis, could represent delayed healingwithin the
stented segment, correlated to individual response to each stent platform.
As discussed above, this apparently more sustained inﬂammation within
G2 DES cannot be assumed as a general rule in their healing response,
neither can be directly correlated to a worse prognosis.
The mean follow-up was 29 months for G1 and 11 for G2 DES. Even
if sufﬁcient to show neo-atherosclerosis changes within DES (9), we
cannot exclude that a longer time course would be needed to unmask
further differences in optical ISR between groups (22). Although in
BMS some authors showed that in the long term the probability of
neoatherosclerotic changes rises, the same hypothesis cannot be direct-
ly applied to DES. In these devices the neoatherosclerotic phenomenon
seems to start earlier but no data exist about the evolution overtime.
Our data shows, at least in G1 DES, a lower prevalence of heterogeneous
and neoatherosclerotic patterns in the late follow-up.
In G1 DES PSLIA prevalence decreased, whereas the opposite hap-
pened in G2 ISR, probably revealing a sustained peri-strut inﬂammation
process. Teramoto et al. reported that PSLIA was more frequently
observed with DES than BMS and that these regions were hypocellular
regions, suggesting the presence of ﬁbrinoid or proteoglycans as a
consequence of delayed arterial healing (38). Their role in the possible
progression of neo-atherosclerosis needs further investigation.
3.3. Limitations
The discussion has already focused on some limitations of the study,
correlated to the nature of the registry enrolling selected patients with
angiographically signiﬁcant ISR, and the lack of serial OCT analysis. Fur-
thermore, wewant to underline that OCT has intrinsic limitations in the
qualitative analysis of restenotic tissue and the differentiation of some
patterns was sometimes difﬁcult. OCT ﬁndings were not conﬁrmed bySecond generation (n = 641) p p* p**
≤1 year (n = 496) N1 year (n = 145)
155 (31.2) 32 (22.1) 0.04 b0.01 b0.01
283 (57.1) 85 (58.6) 0.70 b0.01 b0.01
40 (14.1) 26 (31.7)
211 (7.5) 5 0(58.8)
32 (11.3) 9 (10.6)
58(11.7) 28(19.3) 0.01 b0.01 b0.01
49 (9.9) 26 (17.9) 0.01 b0.01 b0.01
7 (1.4) 4 (2.8) 0.28 b0.01 0.27
2 (0.4) 0 (0.0) 0.98 0.32 0.61
3 (0.6) 0 (0.0) 0.35 0.56 0.60
1 (0.2) 1 (0.7) 0.35 b0.01 0.44
57 (11.5) 39 (26.9) b0.01 0.11 b0.01
36 (7.3) 11 (7.6) 0.86 0.19 0.75
4 (0.8) 1 (0.7) 0.89 0.11 0.65
15 (3.0) 2 (1.4) 0.39 0.08 0.41
tomography; PSLIA: peri-strut low intensity area. p: comparison within each DES genera-
nerations.
Fig. 4. Absolute prevalence of themain optical patterns of in-stent restenosis according to
DES generations and early or late phase of follow-up. For statistical signiﬁcance refer to
Table 4.
74 K. Kilickesmez et al. / IJC Heart & Vessels 3 (2014) 68–74histopathological analysis and come from observations in a relatively
small number of patients.
4. Conclusions
When ISR restenosis occurs in second generation DES, the current
data suggest a different time course and differentmorphological charac-
teristics from ﬁrst generation. Future prospective studies should evalu-
ate the relationship between ISR morphology, time course and clinical
events.
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